Teva is a strategic partner of EU healthcare systems, producing 96% of its European generic, biosimilar and innovative portfolio in plants across 13 European countries. In 2024, Teva saved healthcare systems over 2.9billion and supported more than 100,000 jobs. A significant share of our portfolio, especially offpatent medicines, is procured through public tenders.
TPE
Teva Pharmaceuticals Europe
Company · ISR · EU Transparency Register 27116427434-57
14
positions filed
in the 665 files tracked
12
legislative files
of 665 tracked
3
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #97 by legislative files engaged, a count of participation, not a measure of influence.
2
declared lobbying FTE
self-declared
€600K+
declared costs / yr (floor)
2
EP accreditations
as declared to the register
2011
in the register since
Declares membership of
- Medicines for Europe - https://www.medicinesforeurope.com/
- EFPIA - https://www.efpia.eu/about-us/membership/
- Within CEFIC :
- > EFCG (European Fine Chemicals Group - a CEFIC group) - https://efcg.cefic.org/
- > APIC (Active Pharmaceuticals Ingredients Committee) - https://www.apic.cefic.org/
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Registered as
- Teva Pharmaceuticals Europe BV (Teva)
- Head office
- Haarlem, Netherlands
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Teva in PolicySpeak: request access →
Work at Teva Pharmaceuticals Europe? so we know who speaks for it.
Their record over time
Teva Pharmaceuticals Europe filed 14 positions between 6 Jan 2021 and 26 Jan 2026, across 12 of the 665 legislative files tracked here, attaching a full position paper 3 times.
2021 · 4 filed2022 · 2 filed2023 · 6 filed2025 · 1 filed2026 · 1 filed
What they argued
Teva is a strategic partner of EU healthcare systems, producing 96% of its European generic, biosimilar and innovative portfolio in plants across 13 European countries. In 2023, Teva saved the healthcare systems more than 2.9 billion EUR across 13 European countries in which we support more than 120,000 jobs.
At Teva Pharmaceuticals, our mission is to improve the lives of patients across the globe. In Europe, Teva is a strategic partner of healthcare systems, producing 96 % of its European generic, biosimilar and innovative portfolio in plants across 15 European countries. As a company focused on improving the health of patients, the environment has always been central to Teva.
Teva is a strategic partner of EU healthcare systems, producing 96% of its European generic, biosimilar and innovative portfolio in plants across 15 European countries. In 2020 Teva saved the healthcare systems more than 8.4 billion EUR across 9 European countries in which we support more than 105,000 jobs.
Teva is a strategic partner of EU healthcare systems, producing 96% of its European generic, biosimilar and innovative portfolio in plants across 15 European countries. In 2020 Teva saved the healthcare systems more than 8.4 billion EUR across 9 European countries in which we support more than 105,000 jobs.
Teva is a strategic partner of EU healthcare systems, producing 93% of its European generic, biosimilar and innovative portfolio in plants across 15 European countries (53% of our APIs are manufactured in house, 40% of which is in Europe), and saving healthcare systems more than €7.5B across 12 countries in which we support more than 112,600 jobs.
Teva is a strategic partner of EU healthcare systems, producing 96% of its European generic, biosimilar and innovative portfolio in plants across 15 European countries. In 2020 Teva saved the healthcare systems more than 8.4. billion EUR across 9 European countries in which we support more than 105,000 jobs.
Teva is a strategic partner of European healthcare systems. Teva is committed to researching and developing new therapeutic options for unmet medical needs and improving affordable and equitable access to quality medicines.
Teva is a strategic partner of EU healthcare systems, producing 96% of its European generic, biosimilar and innovative portfolio in plants across 15 European countries (53% of our APIs are manufactured in house, 40% of which are in Europe), and in 2020 saving healthcare systems more than 8.4. billion EUR across 9 European countries in which we support more than 105,000 jobs.
At Teva Pharmaceuticals, our mission is to improve the lives of patients across the globe. In Europe, Teva is a strategic partner of healthcare systems, producing 96% of its European generic, biosimilar and innovative portfolio in plants across 15 European countries. As a company focused on improving the health of patients, the environment is very central to Teva, which is reflected in our commitments.
As a leading global pharmaceutical company, Teva provides medicines to more than 200 million patients around the world every day. Ensuring patients get access to their treatments when they need them is at the heart of our mission. Therefore, addressing and preventing shortages and guaranteeing security of supply is a priority for Teva, including during health emergencies situations.
Teva is a strategic partner of EU healthcare systems, producing 96% of its European generic, biosimilar and innovative portfolio in plants across 15 European countries. In addition, 53% of our APIs are manufactured in house, 40% of which is in Europe, and in 2020 Teva saved healthcare systems more than 8.4. billion EUR across 9 European countries in which we support more than 105,000 jobs.
Teva provides medicines to more than 200 million patients around the world every day. Our mission is to improve the lives of patients across the globe. As proven during the COVID-19, a vibrant dialogue between competent authorities, policy makers and industry is needed to achieve our common objectives to secure sustainable and equitable access to medicines for patients.
At Teva pharmaceuticals, our mission is to improve the lives of patients across the globe. In Europe, Teva is a strategic partner of healthcare systems, producing 96% of its European generic, biosimilar and innovative portfolio in plants across 15 European countries (53% of our APIs are manufactured in-house, 40% of which are in Europe), and 2020 saving healthcare systems more than 8.4.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Teva Pharmaceuticals Europe next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 298.
Is this your organization?
Everything on this page comes from Teva Pharmaceuticals Europe’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.